ProfileGDS5678 / 1431407_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 64% 62% 62% 61% 61% 65% 67% 62% 61% 61% 62% 61% 63% 62% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8765264
GSM967853U87-EV human glioblastoma xenograft - Control 23.7053462
GSM967854U87-EV human glioblastoma xenograft - Control 33.7083462
GSM967855U87-EV human glioblastoma xenograft - Control 43.6002461
GSM967856U87-EV human glioblastoma xenograft - Control 53.6171161
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.9505465
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0814567
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7150662
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.6396461
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6611461
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7086262
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6169561
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7814363
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7122562